<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04338659</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI322A102</org_study_id>
    <nct_id>NCT04338659</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IBI322 in American Subjects With Advanced Malignant Tumors</brief_title>
  <official_title>A Phase 1a Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Advanced Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study evaluating the safety, tolerability and preliminary efficacy of
      IBI322 in cancer subjects who failed standard treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of DLT time</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatment related AEs</measure>
    <time_frame>90 days post last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters: The area under the curve (AUC)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: Maximum concentration (Cmax)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: Time at which maximum concentration (Tmax)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: The half-life (t1/2)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive rate of ADA and Nab</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive rate of Circulating Immune Complex</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>IBI322</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI322</intervention_name>
    <description>Recombinant anti-human CD47/PD-L1 bispecific antibody injection</description>
    <arm_group_label>IBI322</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically/cytologically confirmed, locally advanced unresectable or metastatic
             tumors.

          2. At least one evaluable lesion.

          3. Male or female subject above 18 years old.

          4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) performance status 0
             or 1.

          5. Must have adequate organ function

        Exclusion Criteria：

          1. Previous exposure to any anti-CD47 monoclonal antibody, SIRPα antibody, or CD47/SIRPα
             recombinant protein.

          2. Previous exposure to any anti-programmed death receptor 1 (PD-1) or anti-programmed
             death ligand 1 (PD-L1) /anti-programmed death ligand 2 (PD-L2) antibodies

          3. Subjects participating in another interventional clinical study, except for:
             observational (non-interventional) clinical studies or survival follow-up phase of
             interventional studies.

          4. Patients who are on anticoagulants and /or require concomitant aspirin or other
             nonsteroids anti-inflammatory medications. Patients with a history of a bleeding
             diathesis (von Willebrand disease, end stage liver disease, hemophilia, etc.)

          5. Subjects who have a history of blood transfusion within 2 weeks prior to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tong Wu</last_name>
    <phone>0512-69566088</phone>
    <email>tong.wu01@innoventbio.com</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

